|
FY2021
12 months to Nov 30, 2021
|
|
|---|---|
| OPERATING ACTIVITIES | |
| Loss for the year | |
| Adjustment for non-cash items: | |
| Depreciation and amortization | |
| Share-based payments | |
| Inventory valuation allowance | |
| Fair value changes on growth of biological assets and inventory sold | |
| Impairment loss on trade receivables | |
| Provision (recovery) for income taxes | |
| Interest expense on lease liability | |
| Accretion | |
| Foreign exchange (gain) loss | |
| Interest income on promissory note receivable | |
| Loss (gain) on disposal of capital assets | |
| Gain on marketable securities and derivatives | |
| Gain on remeasurement of contingent consideration | |
| Working capital adjustments: | |
| Trade and other receivables | |
| Prepaid expenses and other current assets | |
| Inventory and biological assets | |
| Contractual obligation | |
| Accounts payable and accrued liabilities | |
| Income taxes (paid) recovered | |
| Operating activities | |
| INVESTING ACTIVITIES | |
| Acquisition of property, plant and equipment | |
| Acquisition of intangible assets | |
| Purchase of marketable securities and derivatives | |
| Repayment of promissory note receivable | |
| Proceeds from sale of capital assets | |
| Proceeds from sale of marketable securities and derivatives | |
| Issuance of promissory note receivable | |
| Investing activities | |
| FINANCING ACTIVITIES | |
| Proceeds from bought deal, net of share issue costs | |
| Proceeds from exercise of warrants | |
| Proceeds from exercise of stock options | |
| Payment on exercise of RSUs | |
| Payment to settle obligation to issue shares | |
| Repayments of term loan | |
| Payments on lease liability | |
| Financing activities | |
| Effect of exchange rate changes on cash | |
| CHANGE IN CASH | |
| Cash, beginning of year | |
| Cash, end of year |
Loading...
